Price range: $325.00 through $1,350.00
SS-31, also known as Elamipretide, is a mitochondria-targeted tetrapeptide studied for its interaction with cardiolipin and its role in mitochondrial membrane stability. Within controlled laboratory environments, SS-31 is evaluated for its influence on oxidative stress pathways, ATP production efficiency, and cellular bioenergetics.
Unlike receptor-agonist peptides, SS-31 is investigated for its intracellular mitochondrial targeting properties, making it a compound of interest in advanced metabolic and cellular resilience research models.
Research Name: SS-31
Alias: Elamipretide
Category: Mitochondrial-targeted peptide
Primary Research Focus: Mitochondrial membrane stabilization, oxidative stress modulation, bioenergetic signaling
Format: Lyophilized powder
Upon reconstitution with an appropriate volume of bacteriostatic water, final concentration will vary depending on total diluent added. Researchers calculate concentration using the standard formula:
Total mg in vial ÷ Total mL added = mg per mL
For U-100 insulin syringes:
1 mL = 100 units
Units required are determined by dividing the desired mg amount by the final mg/mL concentration.
SS-31 is studied for its potential influence on:
Mitochondrial Function
Cardiolipin interaction modeling
Electron transport chain stability
ATP production efficiency
Oxidative Stress Pathways
Reactive oxygen species (ROS) signaling
Mitochondrial membrane integrity
Cellular stress-response frameworks
Energy & Endurance Modeling
Skeletal muscle bioenergetics
Cardiac tissue metabolic studies
Cellular fatigue and recovery signaling
Its intracellular targeting mechanism differentiates SS-31 from metabolic receptor agonists or endocrine-modulating peptides.
Within structured research environments, investigators may observe:
Dose-dependent variables
Energy-utilization shifts
Mitochondrial marker fluctuations
Oxidative stress indicator changes
Metabolic observations
Endurance-capacity trends
Tissue-specific bioenergetic variation
Less frequent observations
Mild headache
Injection-site irritation
Temporary fatigue during adaptation phases
Monitoring often focuses on mitochondrial biomarkers and oxidative stress parameters.
Administration Frequency: Varies by study design
Common Study Duration: 4–12 weeks
Titration Strategy: Gradual adjustments to evaluate mitochondrial response
Researchers commonly avoid stacking with other potent mitochondrial modulators unless specifically designing combination pathway studies.
Store lyophilized vial in a cool, dry environment.
Refrigerate after reconstitution.
Maintain sterile laboratory handling procedures at all times.
